Public interest and private gain in pharmaceutical regulation

Jess Ennis is a UCD Master of Public Policy student. She considers the conflicts over funding and availability of critical medications – specifically Orkambi for cystic fibrosis sufferers. In July 2015, the FDA approved the combination drug Lumacaftor/ Ivacaftor (Orkambi) which treats the underlying cause of Cystic Fibrosis (CF) for patients with two copies ofContinue reading “Public interest and private gain in pharmaceutical regulation”